Neobavaisoflavone, a flavonoid, is isolated from the seeds of Psoralea corylifolia. Neobavaisoflavone exhibits anti-inflammatory, anti-cancer and anti-oxidation activities. Neobavaisoflavone inhibits DNA polymerase at moderate to high concentrations. Neobavaisoflavone also inhibits platelet aggregation.

Product information

CAS Number: 41060-15-5

Molecular Weight: 322.35

Formula: C20H18O4

Chemical Name: 7-hydroxy-3-[4-hydroxy-3-(3-methylbut-2-en-1-yl)phenyl]-4H-chromen-4-one

Smiles: CC(C)=CCC1=CC(=CC=C1O)C1=COC2=CC(O)=CC=C2C1=O

InChiKey: OBGPEBYHGIUFBN-UHFFFAOYSA-N

InChi: InChI=1S/C20H18O4/c1-12(2)3-4-14-9-13(5-8-18(14)22)17-11-24-19-10-15(21)6-7-16(19)20(17)23/h3,5-11,21-22H,4H2,1-2H3

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO : ≥ 31 mg/mL (96.17 mM)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥360 days if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

Neobavaisoflavone (1-50 μM; 20 h) decreases NO (ED50=25 μM) and cytokine (ED50s=23.11, 5.03, 5.23, 5.26 and 18.80 μM for IL-1β, IL-6, IL-12p40, IL-12p70 and TNF-α, respectively) production in LPS plus IFN-γ-stimulated RAW264.7 macrophages. Neobavaisoflavone (1-100 μM; 30 min) decreases the chemiluminescence in PMA-stimulated RAW264.7 macrophages, with an ED50 of 19.94 μM in activated RAW264.7 cells. Neobavaisoflavone (1-100 μM); 20 h) has no effect on the viability and is not toxic to RAW264.7 cells. Neobavaisoflavone (20-50 μM; 48 h) inhibits prostate cancer cell proliferation by inducing cytotoxicity and apoptosis in a dose-dependent manner. Neobavaisoflavone (2-8 μM; 7 d) inhibits RANKL‐mediated osteoclastogenesis in bone marrow monocytes (BMMCs) and RAW264.7 cells dose dependently at the early stage.

In Vivo:

Neobavaisoflavone (30 mg/kg; i.p. for 6 weeks) inhibits osteoclastogenesis, promotes osteogenesis and ameliorates bone loss in ovariectomized mice.

References:

1. Szliszka E, et, al. Inhibition of inflammatory mediators by neobavaisoflavone in activated RAW264.7 macrophages. Molecules. 2011 May 3;16(5):3701-12.
2. Szliszka E, et, al. Enhanced TRAIL-mediated apoptosis in prostate cancer cells by the bioactive compounds neobavaisoflavone and psoralidin isolated from Psoralea corylifolia. Pharmacol Rep. 2011;63(1):139-48.
3. Chen H, et, al. Neobavaisoflavone inhibits osteoclastogenesis through blocking RANKL signalling-mediated TRAF6 and c-Src recruitment and NF-κB, MAPK and Akt pathways. J Cell Mol Med. 2020 Aug;24(16):9067-9084.
4. Sun NJ, et, al. DNA polymerase and topoisomerase II inhibitors from Psoralea corylifolia. J Nat Prod. 1998 Mar;61(3):362-6.

Products are for research use only. Not for human use.